

PERSONALIZED MEDICINE AND EPIGENOMICS: TECHNOLOGIES AND GLOBAL MARKETS



PHM044C
March 2016

Vijay Laxmi
Project Analyst

ISBN: 1-62296-243-5



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVE	2
TITLE DESCRIPTION	2
SCOPE OF THE REPORT	3
INTENDED AUDIENCE	3
RESEARCH METHODOLOGY	3
ANALYST'S CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	4
DISCLAIMER	4
CHAPTER 2 EXECUTIVE SUMMARY	6
<i>SUMMARY TABLE GLOBAL EPIGENOMIC MARKET BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	6
<i>SUMMARY FIGURE GLOBAL EPIGENOMIC MARKET BY REGION, 2014-2020 (\$ MILLIONS)</i>	7
CHAPTER 3 MARKET OVERVIEW	9
INTRODUCTION	9
NEW PARADIGM OF EPIGENOMICS	9
EPIGENOMICS AS IT FITS WITHIN GENOMICS	10
TECHNICAL SCOPE OF THIS REPORT	10
EPIGENOMIC MARKET POTENTIAL	11
EPIGENOMIC PRODUCTS	11
RESEARCH TOOLS AND REAGENTS	11
DIAGNOSTICS	12
DRUGS	13
<i>TABLE 1 U.S. FOOD AND DRUG ADMINISTRATION-APPROVED EPIGENETIC THERAPIES</i>	13
<i>TABLE 2 SELECTED EPIGENETIC THERAPIES IN CLINICAL DEVELOPMENT</i>	15
GROWTH DRIVING FORCES	15
GROWTH IN LIFE SCIENCE FUNDING	16
EPIGENOMIC MAP CREATION	16
AGING POPULATIONS IN DEVELOPED COUNTRIES	17
NEED FOR BETTER CANCER THERAPIES	17
GROWTH IN PERSONALIZED MEDICINE	18
IMPORTANCE OF EPIGENETIC TECHNOLOGY	18
LIFECYCLE STATUS OF EPIGENOMIC TECHNOLOGIES	18
HISTORICAL BACKGROUND	18
EPIGENOMIC INDUSTRY	19
CHAPTER 4 EPIGENETIC DRUGS ON THE MARKET AND IN THE PIPELINE	21
OVERVIEW	21
DRUG CLASSIFICATION	21
<i>TABLE 3 EPIGENETIC DRUG CLASSIFICATION WITH THERAPEUTIC POTENTIAL</i>	21
DNMT INHIBITORS	22

TOPIC	PAGE NO.
Nucleoside Analogue Inhibitors	22
Non-Nucleoside Analogue Inhibitors	22
Antisense Oligonucleotides	23
<i>TABLE 4 CLASSIFICATION ACCORDING TO POTENTIAL THERAPEUTIC USES AND DEVELOPMENTAL PHASES, 2005-2015</i>	23
DNA METHYLATION	24
DNA Methyltransferases	24
<i>FIGURE 1 AZAC AND 5-AZADC MECHANISM OF ACTION</i>	24
HISTONE DEACETYLASE INHIBITORS	25
Histone Deacetylase Inhibitors' Roles in Mental Health	25
Histone Deacetylase Inhibitors Roles in Other Health Conditions	26
Epigenetic Drug Combinations	26
<i>FIGURE 2 EPIGENETIC CHANGES IN CANCER INVOLVING THE METHYLATION OF TUMOR-SUPPRESSION GENES AND THE DEMETHYLATION OF PROMETASTATIC GENES</i>	26
EMERGING THERAPIES	27
LARGE-SCALE REGIONAL EPIGENOMIC PROJECTS	27
ENCYCLOPEDIA OF DNA ELEMENTS	28
INTERNATIONAL HUMAN EPIGENOME CONSORTIUM	29
Blueprint	30
Epigenomic Platform Program (Canada)	31
DEEP (Germany)	31
CREST/IHEC, Team Japan (Asia)	32
National Institutes of Health Roadmap Epigenomic Project	32
OTHER REGIONAL PROJECTS	33
Asia-Pacific Projects	33
Canadian and Australian Projects	33
European Epigenomic Projects	33
CHAPTER 5 PERSONALIZED MEDICINE BASED ON THERAPEUTICS	35
OVERVIEW	35
MARKET DYNAMICS	36
<i>FIGURE 3 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR CANCER TREATMENT, 2014-2020</i>	36
EPIGENETIC PERSONALIZED MEDICINE FOR CANCER TREATMENT	37
HEMATOLOGICAL CANCERS	37
<i>TABLE 5 FOOD AND DRUG ADMINISTRATION-APPROVED EPIGENETIC THERAPIES, 2004-2015</i>	38
SOLID TUMORS	38
GASTRIC CANCER	39
LUNG CANCER	40
COLORECTAL CANCERS	40
EPIGENETIC PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS	40
HUNTINGTON'S DISEASE	41
ALZHEIMER'S DISEASE	42
DEPRESSION	42
MENTAL RETARDATION	43
PARKINSON'S DISEASE	44

TOPIC	PAGE NO.
EPIGENETIC PERSONALIZED MEDICINE FOR CARDIOVASCULAR DISEASES	44
EPIGENETIC PERSONALIZED MEDICINE FOR OTHERS	45
MYELODYSPLASTIC SYNDROMES	45
<i>TABLE 6 CLINICAL PICTURE OF PERSONALIZED MEDICINE IN MYELODYSPLASTIC SYNDROMES (2015)</i>	45
OBESITY	45
DIABETES	45
RHEUMATOID ARTHRITIS	46
MULTIPLE SCLEROSIS	46
<i>TABLE 7 EPIGENETIC MECHANISMS IMPLICATED IN MULTIPLE SCLEROSIS PATHOGENESIS</i>	46
INFLAMMATORY BOWEL DISEASES	47
CHAPTER 6 EPIGENETIC THERAPIES	49
STEM CELL THERAPIES	49
DIABETES	49
MENTAL DISORDERS	49
SEASONAL AFFECTIVE DISORDER	49
UNIPOLAR DEPRESSION	50
DYSTHYMIA OR DYSTHYMIA DISORDER	50
ATYPICAL DEPRESSION	50
PSYCHOTIC DEPRESSION	50
CHAPTER 7 BIOMARKER TECHNIQUES	53
BIOMARKER DISCOVERY: DNA METHYLATION FOR CANCER DETECTION DNA METHYLATION	53
CHROMATIN REMODELING	54
MIRNAS	54
miRNA Detection	54
MARKET DYNAMICS FOR EPIGENETIC DRUGS AND BIOMARKER DISCOVERY	55
DRIVERS	55
Increasing Prevalence of Cancer and Other Chronic Diseases	55
<i>TABLE 8 GLOBAL CANCER INCIDENCES, 2012</i>	56
Growing Global Geriatric Population Base	56
<i>FIGURE 4 POPULATION AGE 65 AND OLDER, 2010-2030 (%)</i>	57
Increasing Collaborations between Biotechnology and Pharmaceutical Companies and Academic Research Institutes	58
<i>TABLE 9 MAJOR COLLABORATIONS IN THE EPIGENETIC MARKET, 2011-2015</i>	58
Presence of Funding Programs to Promote and Support Research and Development	59
<i>TABLE 10 KEY GLOBAL ORGANIZATIONS FUNDING EPIGENOMICS RELATED R&D, 2004-2015</i>	59
Introduction of Technological Advancements	59
RESTRAINTS	60
Inefficiency to Identification and Validation of Biomarkers	60
Presence of Complicated Regulatory Framework	60
CHAPTER 8 EPIGENETIC NON-CANCER DIAGNOSIS	62
<i>FIGURE 5 EPIGENOMIC ANALYSIS</i>	62

TOPIC	PAGE NO.
NEURO	62
ALZHEIMER'S DISEASE	63
RESEARCH AND DEVELOPMENT	63
DEPRESSION	64
MENTAL RETARDATION	64
CARDIOVASCULAR DISEASE	65
<i>TABLE 11 GLOBAL IMPACT OF CARDIOVASCULAR DISEASE, 2013 (MILLIONS)</i>	65
<i>FIGURE 6 POPULATION AFFECTED IN HIGH-, MIDDLE- AND LOW-INCOME COUNTRIES BY TYPE OF HEART DISEASE, 2012 (%)</i>	66
<i>FIGURE 7 GLOBAL CARDIOVASCULAR DISEASE PERCENTAGE, 2012 (%)</i>	66
RESEARCH AND DEVELOPMENT IN EPIGENETICS CREATING HUGE SCOPE	67
<i>FIGURE 8 EPIGENETIC ADVANCEMENT IN CARDIOVASCULAR DISEASES</i>	67
HEART FAILURE	68
INFLAMMATORY AND AUTOIMMUNE DISEASE	69
RHEUMATOID ARTHRITIS	69
DIABETES	69
MULTIPLE SCLEROSIS	70
<i>FIGURE 9 EPIGENETICS MECHANISM</i>	70
INFLAMMATORY BOWEL DISEASES	71
LUPUS	71
RESEARCH AND DEVELOPMENT	72
DNA METHYLATION IN CANCER DETECTION	72
IDENTIFICATION OF EPIGENETIC BIOMARKERS FOR DIAGNOSIS AND PREDICTION	73
MECHANISMS OF EPIGENETIC GENE SILENCING	73
CHAPTER 9 EPIGENETIC APPLICATIONS	76
EPIGENETICS DURING EARLY EMBRYONIC STAGES	76
PRE-IMPLANTATION REPROGRAMMING	76
Fusion and Cleavage	76
Demethylation and Remethylation in Early Embryos	76
Epigenetic Reprogramming in Later Development	77
Gene Expression and its Development in Clones and Technical Contributions	77
GAMETOGENIC REPROGRAMMING	78
MITOCHONDRIAL HETEROPLASMY	78
IMPLICATIONS OF EPIGENETIC REPROGRAMMING ON ANIMAL HEALTH AND FOOD CONSUMPTION RISKS	79
REPROGRAMMING FACTORS	80
EPIGENETIC PROFILE OF MESENCHYMAL STEM CELLS IN CULTURE	81
<i>TABLE 12 INDICATIONS AND OUTCOMES</i>	81
CHAPTER 10 EPIGENOMICS: REGIONAL ANALYSIS	84
OVERVIEW	84
NORTH AMERICA	84
<i>FIGURE 10 NORTH AMERICAN EPIGENOMIC MARKET, 2014-2020 (\$ MILLIONS)</i>	84
<i>TABLE 13 NORTH AMERICAN EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 (\$ MILLIONS)</i>	85

TOPIC	PAGE NO.
TABLE 14 NORTH AMERICAN EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH 2020 (\$ MILLIONS)	86
TABLE 15 NORTH AMERICAN EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	86
TABLE 16 NORTH AMERICAN EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY, THROUGH 2020 (\$ MILLIONS)	86
TABLE 17 NORTH AMERICAN EPIGENOMIC MARKET BY APPLICATION AREA, THROUGH 2020 (\$ MILLIONS)	87
TABLE 18 NORTH AMERICAN EPIGENETIC PERSONALIZED MEDICINE FOR CANCER TREATMENT MARKET BY TYPE, THROUGH 2020 (\$ MILLIONS)	87
TABLE 19 NORTH AMERICAN EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 (\$ MILLIONS)	88
TABLE 20 NORTH AMERICAN EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BASED ON THERAPEUTICS, THROUGH 2020 (\$ MILLIONS)	89
TABLE 21 NORTH AMERICA EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, THROUGH 2020 (\$ MILLIONS)	89
TABLE 22 NORTH AMERICAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR OTHERS, THROUGH 2020 (\$ MILLIONS)	90
TABLE 23 NORTH AMERICAN EPIGENETIC THERAPIES MARKET, THROUGH 2020 (\$ MILLIONS)	90
TABLE 24 NORTH AMERICAN BIOMARKER MARKET, THROUGH 2020 (\$ MILLIONS)	91
TABLE 25 NORTH AMERICAN MARKET FOR HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION, THROUGH 2020 (\$ MILLIONS)	92
TABLE 26 NORTH AMERICAN EPIGENETIC DIAGNOSTIC MARKET, THROUGH 2020 (\$ MILLIONS)	92
TABLE 27 NORTH AMERICAN EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	93
TABLE 28 NORTH AMERICAN EPIGENETIC CARDIOVASCULAR DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	94
TABLE 29 NORTH AMERICAN EPIGENETIC INFLAMMATORY AND AUTOIMMUNE DISEASE DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	94
TABLE 30 NORTH AMERICAN EPIGENOMIC RESEARCH AND DEVELOPMENT MARKET, THROUGH 2020 (\$ MILLIONS)	95
ASIA-PACIFIC	96
FIGURE 11 ASIA-PACIFIC EPIGENOMIC MARKET, 2014-2020 (\$ MILLIONS)	96
TABLE 31 ASIA-PACIFIC EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 (\$ MILLIONS)	97
TABLE 32 ASIA-PACIFIC EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH 2020 (\$ MILLIONS)	97
TABLE 33 ASIA-PACIFIC EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	98
TABLE 34 ASIA-PACIFIC EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY, THROUGH 2020 (\$ MILLIONS)	98
TABLE 35 ASIA-PACIFIC EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	99
TABLE 36 ASIA-PACIFIC EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR CANCER TREATMENT, THROUGH 2020 (\$ MILLIONS)	99
TABLE 37 ASIA-PACIFIC EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 (\$ MILLIONS)	100
TABLE 38 ASIA-PACIFIC EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BY THERAPEUTIC, THROUGH 2020 (\$ MILLIONS)	100

TOPIC	PAGE NO.
TABLE 39 ASIA-PACIFIC EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, THROUGH 2020 (\$ MILLIONS)	101
TABLE 40 ASIA-PACIFIC EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR OTHERS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	101
TABLE 41 ASIA-PACIFIC EPIGENETIC THERAPY MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	102
TABLE 42 ASIA-PACIFIC BIOMARKER MARKET, THROUGH 2020 (\$ MILLIONS)	103
TABLE 43 ASIA-PACIFIC HISTONIC MODIFICATION AS A BIOMARKER IN CANCER DETECTION MARKET, THROUGH 2020 (\$ MILLIONS)	104
TABLE 44 ASIA-PACIFIC EPIGENETIC DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	104
TABLE 45 ASIA-PACIFIC EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	105
TABLE 46 ASIA-PACIFIC EPIGENETIC MARKET FOR CARDIOVASCULAR DIAGNOSIS, THROUGH 2020 (\$ MILLIONS)	105
TABLE 47 ASIA-PACIFIC EPIGENETIC MARKET FOR INFLAMMATORY AND AUTOIMMUNE DISEASE DIAGNOSIS, THROUGH 2020 (\$ MILLIONS)	106
TABLE 48 ASIA-PACIFIC EPIGENETIC MARKET FOR RESEARCH AND DEVELOPMENT, THROUGH 2020 (\$ MILLIONS)	107
EUROPE	108
FIGURE 12 EUROPE EPIGENOMIC MARKET, 2014-2020 (\$ MILLIONS)	108
TABLE 49 EUROPEAN EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 (\$ MILLIONS)	109
TABLE 50 EUROPEAN EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH (\$ MILLIONS)	109
TABLE 51 EUROPEAN EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	110
TABLE 52 EUROPEAN EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY, THROUGH 2020 (\$ MILLIONS)	110
TABLE 53 EUROPEAN EPIGENOMIC MARKET BY APPLICATION AREA, THROUGH 2020 (\$ MILLIONS)	110
TABLE 54 EUROPEAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR CANCER TREATMENT BY DIAGNOSIS, THROUGH 2020 (\$ MILLIONS)	111
TABLE 55 EUROPEAN EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 (\$ MILLIONS)	111
TABLE 56 EUROPEAN EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BASED ON THERAPEUTICS, THROUGH 2020 (\$ MILLIONS)	112
TABLE 57 EUROPEAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, THROUGH 2020 (\$ MILLIONS)	113
TABLE 58 EUROPEAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR OTHERS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	113
TABLE 59 EUROPEAN EPIGENETIC THERAPIES MARKET, THROUGH 2020 (\$ MILLIONS)	114
TABLE 60 EUROPEAN BIOMARKER MARKET, THROUGH 2020 (\$ MILLIONS)	115
TABLE 61 EUROPEAN HISTONIC MODIFICATION AS BIOMARKER MARKET IN CANCER DETECTION, THROUGH 2020 (\$ MILLIONS)	115
TABLE 62 EUROPEAN EPIGENETIC DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	116
TABLE 63 EUROPEAN EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	116
TABLE 64 EUROPEAN EPIGENETIC CARDIOVASCULAR DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	117

TOPIC	PAGE NO.
<i>TABLE 65 EUROPEAN EPIGENETIC INFLAMMATORY AND AUTOIMMUNE DISEASE DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)</i>	117
<i>TABLE 66 EUROPEAN EPIGENETIC RESEARCH AND DEVELOPMENT, THROUGH 2020 (\$ MILLIONS)</i>	118
LATIN AMERICA	119
<i>FIGURE 13 LATIN AMERICAN EPIGENOMIC MARKET, 2014-2020 (\$ MILLIONS)</i>	119
<i>TABLE 67 LATIN AMERICAN EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 (\$ MILLIONS)</i>	120
<i>TABLE 68 LATIN AMERICAN EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH 2020 (\$ MILLIONS)</i>	120
<i>TABLE 69 LATIN AMERICAN EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	121
<i>TABLE 70 LATIN AMERICAN EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY, THROUGH 2020 (\$ MILLIONS)</i>	121
<i>TABLE 71 LATIN AMERICAN EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	121
<i>TABLE 72 LATIN AMERICAN EPIGENETIC PERSONALIZED MEDICINE FOR CANCER TREATMENT BY DIAGNOSIS, THROUGH 2020 (\$ MILLIONS)</i>	122
<i>TABLE 73 LATIN AMERICAN EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 (\$ MILLIONS)</i>	123
<i>TABLE 74 LATIN AMERICAN EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BASED ON THERAPEUTICS, THROUGH 2020 (\$ MILLIONS)</i>	123
<i>TABLE 75 LATIN AMERICAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, THROUGH 2020 (\$ MILLIONS)</i>	124
<i>TABLE 76 LATIN AMERICAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR OTHERS BY DIAGNOSIS, THROUGH 2020 (\$ MILLIONS)</i>	124
<i>TABLE 77 LATIN AMERICAN EPIGENETIC THERAPY MARKET, THROUGH 2020 (\$ MILLIONS)</i>	125
<i>TABLE 78 LATIN AMERICAN BIOMARKER MARKET, THROUGH 2020 (\$ MILLIONS)</i>	126
<i>TABLE 79 LATIN AMERICAN HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION MARKET, THROUGH 2020 (\$ MILLIONS)</i>	126
<i>TABLE 80 LATIN AMERICAN EPIGENETIC DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)</i>	127
<i>TABLE 81 LATIN AMERICAN EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)</i>	127
<i>TABLE 82 LATIN AMERICAN EPIGENETIC CARDIOVASCULAR DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)</i>	128
<i>TABLE 83 LATIN AMERICAN EPIGENETIC INFLAMMATORY AND AUTOIMMUNE DISEASE DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)</i>	129
<i>TABLE 84 LATIN AMERICAN EPIGENETIC RESEARCH AND DEVELOPMENT, THROUGH 2020 (\$ MILLIONS)</i>	129
MIDDLE EAST AND AFRICA	130
<i>FIGURE 14 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET, 2014-2020 (\$ MILLIONS)</i>	130
<i>TABLE 85 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 (\$ MILLIONS)</i>	131
<i>TABLE 86 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH 2020 (\$ MILLIONS)</i>	131
<i>TABLE 87 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	132
<i>TABLE 88 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY, THROUGH 2020 (\$ MILLIONS)</i>	132

TOPIC	PAGE NO.
TABLE 89 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY APPLICATION AREA, THROUGH 2020 (\$ MILLIONS)	133
TABLE 90 MIDDLE EAST AND AFRICA EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR CANCER TREATMENT BY TYPE, THROUGH 2020 (\$ MILLIONS)	133
TABLE 91 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 (\$ MILLIONS)	134
TABLE 92 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BASED ON THERAPEUTICS, THROUGH 2020 (\$ MILLIONS)	135
TABLE 93 MIDDLE EAST AND AFRICA EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, THROUGH 2020 (\$ MILLIONS)	135
TABLE 94 MIDDLE EAST AND AFRICA EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR OTHERS BY DIAGNOSIS, THROUGH 2020 (\$ MILLIONS)	135
TABLE 95 MIDDLE EAST AND AFRICA EPIGENETIC THERAPY MARKET, THROUGH 2020 (\$ MILLIONS)	136
TABLE 96 MIDDLE EAST AND AFRICA BIOMARKER MARKET, THROUGH 2020 (\$ MILLIONS)	137
TABLE 97 MIDDLE EAST AND AFRICA HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION MARKET, THROUGH 2020 (\$ MILLIONS)	138
TABLE 98 MIDDLE EAST AND AFRICA EPIGENETIC DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	138
TABLE 99 MIDDLE EAST AND AFRICA EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	138
TABLE 100 MIDDLE EAST AND AFRICA EPIGENETIC CARDIOVASCULAR DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	139
TABLE 101 MIDDLE EAST AND AFRICA EPIGENETIC INFLAMMATORY AND AUTOIMMUNE DISEASE DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	140
TABLE 102 MIDDLE EAST AND AFRICA EPIGENETIC RESEARCH AND DEVELOPMENT, THROUGH 2020 (\$ MILLIONS)	141
CHAPTER 11 PRODUCT ANALYSIS	143
REAGENTS	143
FIGURE 15 GLOBAL EPIGENOMIC MARKET FOR REAGENTS, 2014-2020 (\$ MILLIONS)	143
TABLE 103 GLOBAL EPIGENOMIC MARKET FOR REAGENTS BY REGION, THROUGH 2020 (\$ MILLIONS)	144
KITS	144
FIGURE 16 GLOBAL EPIGENOMIC MARKET FOR KITS, 2014-2020 (\$ MILLIONS)	144
TABLE 104 GLOBAL EPIGENOMIC MARKET FOR KITS BY REGION, THROUGH 2020 (\$ MILLIONS)	146
INSTRUMENTS	146
FIGURE 17 GLOBAL EPIGENOMIC MARKET FOR INSTRUMENTS, 2014-2020 (\$ MILLIONS)	146
TABLE 105 GLOBAL EPIGENOMIC MARKET FOR INSTRUMENTS BY REGION, THROUGH 2020 (\$ MILLIONS)	147
ENZYMES	147
FIGURE 18 GLOBAL EPIGENOMIC MARKET FOR ENZYMES, 2014-2020 (\$ MILLIONS)	147
TABLE 106 GLOBAL EPIGENOMIC MARKET FOR ENZYMES BY REGION, THROUGH 2020 (\$ MILLIONS)	148
SERVICES	149
FIGURE 19 GLOBAL EPIGENOMIC MARKET FOR SERVICES, 2014-2020 (\$ MILLIONS)	149
TABLE 107 GLOBAL EPIGENOMIC MARKET FOR SERVICES BY REGION, THROUGH 2020 (\$ MILLIONS)	150

TOPIC	PAGE NO.
CHAPTER 12 ANALYSIS BY TECHNOLOGY	152
DNA METHYLATION	152
<i>FIGURE 20 GLOBAL EPIGENOMIC MARKET IN DNA METHYLATION, 2014-2020 (\$ MILLIONS)</i>	152
<i>TABLE 108 GLOBAL EPIGENOMIC MARKET IN DNA METHYLATION BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	153
HISTONE METHYLATION AND ACETYLATION	153
<i>FIGURE 21 GLOBAL EPIGENOMIC MARKET IN HISTONE METHYLATION AND ACETYLATION, 2014-2020 (\$ MILLIONS)</i>	153
<i>TABLE 109 GLOBAL EPIGENOMIC MARKET IN HISTONE METHYLATION AND ACETYLATION BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	154
MICRORNA MODIFICATION	155
<i>FIGURE 22 GLOBAL EPIGENOMIC MARKET IN MICRORNA MODIFICATION, THROUGH 2020 (\$ MILLIONS)</i>	155
<i>TABLE 110 GLOBAL EPIGENOMIC MARKET IN MICRORNA MODIFICATION BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	155
CHAPTER 13 ANALYSIS BY APPLICATION	158
ONCOLOGY	158
<i>FIGURE 23 GLOBAL EPIGENOMIC MARKET IN ONCOLOGY, 2014-2020 (\$ MILLIONS)</i>	158
<i>TABLE 111 GLOBAL EPIGENOMIC MARKET IN ONCOLOGY BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	159
NON-ONCOLOGY	159
<i>FIGURE 24 GLOBAL EPIGENOMIC MARKET IN NON-ONCOLOGY, 2014-2020 (\$ MILLIONS)</i>	159
<i>TABLE 112 GLOBAL EPIGENOMIC MARKET IN NON-ONCOLOGY, BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	160
CANCER DRUG TECHNOLOGY	161
DNA METHYLTRANSFERASE INHIBITORS	161
<i>FIGURE 25 GLOBAL EPIGENOMIC MARKET IN DNA METHYLTRANSFERASE INHIBITORS, 2014-2020 (\$ MILLIONS)</i>	161
<i>TABLE 113 GLOBAL EPIGENOMIC MARKET IN DNA METHYLTRANSFERASE INHIBITORS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	162
HISTONE DEACETYLASE INHIBITORS	162
<i>FIGURE 26 GLOBAL EPIGENOMIC MARKET IN HISTONE DEACETYLASE INHIBITORS, 2014-2020 (\$ MILLIONS)</i>	162
<i>TABLE 114 GLOBAL EPIGENOMIC MARKET IN NON-ONCOLOGY BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	163
APPLICATION AREAS	164
DIAGNOSIS	164
<i>FIGURE 27 GLOBAL EPIGENOMIC MARKET IN DIAGNOSIS, 2014-2020 (\$ MILLIONS)</i>	164
<i>TABLE 115 GLOBAL EPIGENOMIC MARKET IN DIAGNOSIS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	164
PROGNOSIS	165
<i>FIGURE 28 GLOBAL EPIGENOMIC MARKET IN PROGNOSIS, 2014-2020 (\$ MILLIONS)</i>	165
<i>TABLE 116 GLOBAL EPIGENOMIC MARKET IN PROGNOSIS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	166
THERAPY OPTIMIZATION IN ROUTINE CLINICAL TREATMENT	166

TOPIC	PAGE NO.
<i>FIGURE 29 GLOBAL EPIGENOMIC MARKET FOR THERAPY OPTIMIZATION IN ROUTINE CLINICAL TREATMENT, 2014-2020 (\$ MILLIONS)</i>	166
<i>TABLE 117 GLOBAL EPIGENOMIC MARKET FOR THERAPY OPTIMIZATION IN ROUTINE CLINICAL TREATMENT BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	167
DRUG DISCOVERY	168
<i>FIGURE 30 GLOBAL EPIGENOMIC MARKET IN PROGNOSIS, 2014-2020 (\$ MILLIONS)</i>	168
<i>TABLE 118 GLOBAL EPIGENOMIC MARKET IN DRUG DISCOVERY BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	169
CHAPTER 14 ANALYSIS BY PERSONALIZED MEDICINES	171
<i>FIGURE 31 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR CANCER TREATMENT, 2014-2020 (\$ MILLIONS)</i>	171
<i>TABLE 119 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR CANCER TREATMENT BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	172
<i>FIGURE 32 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, 2014-2020 (\$ MILLIONS)</i>	172
<i>TABLE 120 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	173
PERSONALIZED MEDICINE FOR CARDIOVASCULAR DISEASE	173
<i>FIGURE 33 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR CARDIOVASCULAR DISEASE, 2014-2020 (\$ MILLIONS)</i>	174
<i>TABLE 121 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR CARDIOVASCULAR DISEASE, BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	174
HEMATOLOGICAL CANCERS	175
<i>FIGURE 34 GLOBAL EPIGENOMIC MARKET IN HEMATOLOGICAL CANCERS, 2014-2020 (\$ MILLIONS)</i>	175
<i>TABLE 122 GLOBAL EPIGENOMIC MARKET IN HEMATOLOGICAL CANCERS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	176
Solid Tumors	176
<i>FIGURE 35 GLOBAL EPIGENOMIC MARKET IN SOLID TUMORS, 2014-2020 (\$ MILLIONS)</i>	177
<i>TABLE 123 GLOBAL EPIGENOMIC MARKET IN SOLID TUMORS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	178
GASTRIC CANCER	178
<i>FIGURE 36 GLOBAL EPIGENOMIC MARKET IN GASTRIC CANCER, 2014-2020 (\$ MILLIONS)</i>	178
<i>TABLE 124 GLOBAL EPIGENOMIC MARKET IN GASTRIC CANCER BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	179
LUNG CANCER	180
<i>FIGURE 37 GLOBAL EPIGENOMIC MARKET IN LUNG CANCER, 2014-2020 (\$ MILLIONS)</i>	180
<i>TABLE 125 GLOBAL EPIGENOMIC MARKET IN LUNG CANCER BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	181
PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS	181
HUNTINGTON'S DISEASE	181
<i>FIGURE 38 GLOBAL EPIGENOMIC MARKET IN HUNTINGTON'S DISEASE, 2014-2020 (\$ MILLIONS)</i>	181
<i>TABLE 126 GLOBAL EPIGENOMIC MARKET IN HUNTINGTON'S DISEASE, BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	182
ALZHEIMER'S DISEASE	182

TOPIC	PAGE NO.
<i>FIGURE 39 GLOBAL EPIGENOMIC MARKET IN ALZHEIMER'S DISEASE, 2014-2020 (\$ MILLIONS)</i>	182
<i>TABLE 127 GLOBAL EPIGENOMIC MARKET IN ALZHEIMER'S DISEASE BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	183
DEPRESSION	184
<i>FIGURE 40 GLOBAL EPIGENOMIC MARKET IN DEPRESSION, 2014-2020 (\$ MILLIONS)</i>	184
<i>TABLE 128 GLOBAL EPIGENOMIC MARKET IN DEPRESSION BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	184
MENTAL RETARDATION	185
<i>FIGURE 41 GLOBAL EPIGENOMIC MARKET IN MENTAL RETARDATION, 2014-2020 (\$ MILLIONS)</i>	185
<i>TABLE 129 GLOBAL EPIGENOMIC MARKET IN MENTAL RETARDATION BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	186
PARKINSON'S DISEASE	186
<i>FIGURE 42 GLOBAL EPIGENOMIC MARKET IN PARKINSON'S DISEASE, 2014-2020 (\$ MILLIONS)</i>	186
<i>TABLE 130 GLOBAL EPIGENOMIC MARKET IN PARKINSON'S DISEASE, BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	187
PERSONALIZED MEDICINE FOR OTHERS	187
MYELOYDYSPLASTIC SYNDROMES	187
<i>FIGURE 43 GLOBAL EPIGENOMIC MARKET IN MYELOYDYSPLASTIC SYNDROMES, 2014-2020 (\$ MILLIONS)</i>	188
<i>TABLE 131 GLOBAL EPIGENOMIC MARKET IN MYELOYDYSPLASTIC SYNDROMES BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	188
OBESITY	189
<i>FIGURE 44 GLOBAL EPIGENOMIC MARKET IN OBESITY, 2014-2020 (\$ MILLIONS)</i>	189
<i>TABLE 132 GLOBAL EPIGENOMIC MARKET IN OBESITY, BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	190
DIABETES	190
<i>FIGURE 45 GLOBAL EPIGENOMIC MARKET IN DIABETES, 2014-2020 (\$ MILLIONS)</i>	190
<i>TABLE 133 GLOBAL EPIGENOMIC MARKET IN DIABETES BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	191
RHEUMATOID ARTHRITIS	191
<i>FIGURE 46 GLOBAL EPIGENOMIC MARKET IN RHEUMATOID ARTHRITIS, 2014-2020 (\$ MILLIONS)</i>	191
<i>TABLE 134 GLOBAL EPIGENOMIC MARKET IN RHEUMATOID ARTHRITIS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	192
MULTIPLE SCLEROSIS	193
<i>FIGURE 47 GLOBAL EPIGENOMIC MARKET IN MULTIPLE SCLEROSIS, 2014-2020 (\$ MILLIONS)</i>	193
<i>TABLE 135 GLOBAL EPIGENOMIC MARKET IN MULTIPLE SCLEROSIS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	194
INFLAMMATORY BOWEL DISEASES	194
<i>FIGURE 48 GLOBAL EPIGENOMIC MARKET IN INFLAMMATORY BOWEL DISEASES, 2014-2020 (\$ MILLIONS)</i>	194
<i>TABLE 136 GLOBAL EPIGENOMIC MARKET IN INFLAMMATORY BOWEL DISEASES BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	195
LUPUS	195
<i>FIGURE 49 GLOBAL EPIGENOMIC MARKET IN LUPUS, 2014-2020 (\$ MILLIONS)</i>	195
<i>TABLE 137 GLOBAL EPIGENOMIC MARKET IN LUPUS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	196

TOPIC	PAGE NO.
STEM CELL THERAPIES	197
<i>FIGURE 50 GLOBAL EPIGENOMIC MARKET IN STEM CELL THERAPIES, 2014-2020 (\$ MILLIONS)</i>	197
<i>TABLE 138 GLOBAL EPIGENOMIC MARKET IN STEM CELL THERAPIES BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	197
TISSUE RE-ENGINEERING	198
<i>FIGURE 51 GLOBAL EPIGENOMIC MARKET IN TISSUE RE-ENGINEERING, 2014-2020 (\$ MILLIONS)</i>	198
<i>TABLE 139 GLOBAL EPIGENOMIC MARKET IN TISSUE REENGINEERING BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	199
DIABETES	199
<i>FIGURE 52 GLOBAL EPIGENOMIC MARKET IN DIABETES, 2014-2020 (\$ MILLIONS)</i>	199
<i>TABLE 140 GLOBAL EPIGENOMIC MARKET IN DIABETES BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	200
RHEUMATOID ARTHRITIS	201
<i>FIGURE 53 GLOBAL EPIGENOMIC MARKET IN RHEUMATOID ARTHRITIS, 2014-2020 (\$ MILLIONS)</i>	201
<i>TABLE 141 GLOBAL EPIGENOMIC MARKET IN RHEUMATOID ARTHRITIS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	201
MENTAL DISORDERS	202
<i>FIGURE 54 GLOBAL EPIGENOMIC MARKET IN MENTAL DISORDERS, 2014-2020 (\$ MILLIONS)</i>	202
<i>TABLE 142 GLOBAL EPIGENOMIC MARKET IN MENTAL DISORDERS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	203
CARDIAC DYSFUNCTION	203
<i>FIGURE 55 GLOBAL EPIGENOMIC MARKET IN CARDIAC DYSFUNCTION, 2014-2020 (\$ MILLIONS)</i>	203
<i>TABLE 143 GLOBAL EPIGENOMIC MARKET IN CARDIAC DYSFUNCTION BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	204
CANCER	204
<i>FIGURE 56 GLOBAL EPIGENOMIC MARKET IN CANCER, 2014-2020 (\$ MILLIONS)</i>	205
<i>TABLE 144 GLOBAL EPIGENOMIC MARKET IN CANCER BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	205
BIOMARKER DISCOVERY: DNA METHYLATION FOR CANCER DETECTION	206
<i>FIGURE 57 GLOBAL EPIGENOMIC MARKET IN DNA METHYLATION FOR CANCER DETECTION, 2014-2020 (\$ MILLIONS)</i>	206
<i>TABLE 145 GLOBAL EPIGENOMIC MARKET IN BIOMARKER DISCOVERY: DNA METHYLATION FOR CANCER DETECTION BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	207
HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION	207
<i>FIGURE 58 GLOBAL EPIGENOMIC MARKET IN HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION, 2014-2020 (\$ MILLIONS)</i>	207
<i>TABLE 146 GLOBAL EPIGENOMIC MARKET IN HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	208
<i>FIGURE 59 GLOBAL EPIGENOMICS MARKET IN CHROMATIN REMODELING, 2014-2020 (\$ MILLIONS)</i>	208
<i>TABLE 147 GLOBAL EPIGENOMIC MARKET IN CHROMATIN REMODELING BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	209
NONCODING RNAS	210
<i>FIGURE 60 GLOBAL EPIGENOMIC MARKET IN NONCODING RNAS, 2014-2020 (\$ MILLIONS)</i>	210

TOPIC	PAGE NO.
<i>TABLE 148 GLOBAL EPIGENOMIC MARKET IN NONCODING RNAs BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	211
<i>FIGURE 61 GLOBAL EPIGENOMIC MARKET IN MIRNAS, 2014-2020 (\$ MILLION)</i>	211
<i>TABLE 149 GLOBAL EPIGENOMIC MARKET IN MIRNAS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	212
CHAPTER 15 COMPANY PROFILES	214
ABBOTT LABORATORIES	214
<i>TABLE 150 ABBOTT PRODUCT PORTFOLIO</i>	214
<i>TABLE 151 ABBOTT RECENT DEVELOPMENTS</i>	214
AFFYMETRIX	214
<i>TABLE 152 AFFYMETRIX PRODUCT PORTFOLIO</i>	215
<i>TABLE 153 AFFYMETRIX RECENT DEVELOPMENTS</i>	215
AGILENT TECHNOLOGIES	215
<i>TABLE 154 AGILENT PRODUCT PORTFOLIO</i>	215
<i>TABLE 155 AGILENT'S RECENT DEVELOPMENTS</i>	216
ASTELLAS PHARMACEUTICALS	216
<i>TABLE 156 ASTELLAS PHARMACEUTICALS PRODUCT PORTFOLIO</i>	216
<i>TABLE 157 ASTELLAS PHARMACEUTICALS RECENT DEVELOPMENTS</i>	217
BAYER AG	217
<i>TABLE 158 BAYER PRODUCT PORTFOLIO</i>	217
<i>TABLE 159 BAYER RECENT DEVELOPMENTS</i>	218
BIO VISION	218
<i>TABLE 160 BIO VISION PRODUCT PORTFOLIO</i>	218
<i>TABLE 161 BIO VISION RECENT DEVELOPMENTS</i>	218
CELGENE CORP.	219
<i>TABLE 162 CELGENE PRODUCT PORTFOLIO</i>	219
EMD MILLIPORE	219
<i>TABLE 163 EMD MILLIPORE PRODUCT PORTFOLIO</i>	220
<i>TABLE 164 EMD MILLIPORE RECENT DEVELOPMENTS</i>	220
EPIGENOMICS AG	220
<i>TABLE 165 EPIGENOMICS PRODUCT PORTFOLIO</i>	220
<i>TABLE 166 EPIGENOMICS RECENT DEVELOPMENTS</i>	221
EPIGENTEX	221
<i>TABLE 167 EPIGENTEK PRODUCT PORTFOLIO</i>	221
<i>TABLE 168 EPIGENTEK RECENT DEVELOPMENTS</i>	221
ENVIVO PHARMACEUTICALS (FORUM PHARMACEUTICALS)	222
GILEAD SCIENCES	222
<i>TABLE 169 GILEAD SCIENCES PRODUCT PORTFOLIO</i>	222
<i>TABLE 170 GILEAD SCIENCES RECENT DEVELOPMENTS</i>	223
GLAXOSMITHKLINE	223
<i>TABLE 171 GLAXOSMITHKLINE PRODUCT PORTFOLIO</i>	223
ILLUMINA INC.	223
<i>TABLE 172 ILLUMINA PRODUCT PORTFOLIO</i>	224
<i>TABLE 173 ILLUMINA RECENT DEVELOPMENTS</i>	224
JOHNSON & JOHNSON	224
<i>TABLE 174 JOHNSON & JOHNSON PRODUCT PORTFOLIO</i>	225
KARUS THERAPEUTICS LIMITED	225

TOPIC	PAGE NO.
<i>TABLE 175 KARUS THERAPEUTICS PRODUCT PORTFOLIO</i>	225
LABORATORY CORP. OF AMERICA HOLDINGS	225
<i>TABLE 176 LABCORP PRODUCT PORTFOLIO</i>	226
<i>TABLE 177 LABCORP RECENT DEVELOPMENTS</i>	226
LES LABORATOIRES SERVIER	226
<i>TABLE 178 LES LABORATOIRES SERVIER RECENT DEVELOPMENTS</i>	226
MERCK SHARP & DOHME	227
NATUREWISE BIOTECH & MEDICALS CORP.	227
NOVARTIS PHARMA AG	227
<i>TABLE 179 NOVARTIS PRODUCT PORTFOLIO</i>	228
<i>TABLE 180 NOVARTIS RECENT DEVELOPMENTS</i>	228
ONCOLYS BIOPHARMA INC.	228
<i>TABLE 181 ONCOLYS BIOPHARMA PRODUCT PORTFOLIO</i>	229
<i>TABLE 182 ONCOLYS BIOPHARMA RECENT DEVELOPMENTS</i>	229
ORCHID CHEMICALS & PHARMACEUTICALS LIMITED	229
<i>TABLE 183 ORCHID CHEMICALS & PHARMACEUTICALS PRODUCT PORTFOLIO</i>	230
PROGEN PHARMACEUTICALS LIMITED	230
<i>TABLE 184 PROGEN PHARMA PRODUCT PORTFOLIO</i>	230
QUEST DIAGNOSTICS	230
<i>TABLE 185 QUEST DIAGNOSTICS PRODUCT PORTFOLIO</i>	231
<i>TABLE 186 QUEST DIAGNOSTICS RECENT DEVELOPMENTS</i>	231
ROCHE HOLDING AG	231
<i>TABLE 187 ROCHE'S PRODUCT PORTFOLIO</i>	232
<i>TABLE 188 ROCHE'S RECENT DEVELOPMENTS</i>	232
RUBICON GENOMICS	232
<i>TABLE 189 RUBICON GENOMICS PRODUCT PORTFOLIO</i>	233
<i>TABLE 190 RUBICON GENOMICS RECENT DEVELOPMENTS</i>	233
TAKEDA PHARMACEUTICAL COMPANY LIMITED	233
<i>TABLE 191 TAKEDA PHARMACEUTICALS PRODUCT PORTFOLIO</i>	234
CHAPTER 16 PATENT ANALYSIS	236
LIST OF PATENTS	236
U.S.	236
<i>TABLE 192 U.S. PATENTS, 2011-JULY 2015</i>	236
EUROPEAN AND JAPANESE PATENTS	242
<i>TABLE 193 EUROPEAN AND JAPANESE PATENTS, 2011-JULY 2015</i>	242
JAPANESE PATENTS	242
<i>TABLE 194 JAPANESE PATENTS, 2011--NOVEMBER 2014</i>	242

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL EPIGENOMIC MARKET BY REGION, THROUGH 2020 (\$ MILLIONS)	6
TABLE 1 U.S. FOOD AND DRUG ADMINISTRATION-APPROVED EPIGENETIC THERAPIES	13
TABLE 2 SELECTED EPIGENETIC THERAPIES IN CLINICAL DEVELOPMENT	15
TABLE 3 EPIGENETIC DRUG CLASSIFICATION WITH THERAPEUTIC POTENTIAL	21
TABLE 4 CLASSIFICATION ACCORDING TO POTENTIAL THERAPEUTIC USES AND DEVELOPMENTAL PHASES, 2005-2015	23
TABLE 5 FOOD AND DRUG ADMINISTRATION-APPROVED EPIGENETIC THERAPIES, 2004-2015	38
TABLE 6 CLINICAL PICTURE OF PERSONALIZED MEDICINE IN MYELODYSPLASTIC SYNDROMES (2015)	45
TABLE 7 EPIGENETIC MECHANISMS IMPLICATED IN MULTIPLE SCLEROSIS PATHOGENESIS	46
TABLE 8 GLOBAL CANCER INCIDENCES, 2012	56
TABLE 9 MAJOR COLLABORATIONS IN THE EPIGENETIC MARKET, 2011-2015	58
TABLE 10 KEY GLOBAL ORGANIZATIONS FUNDING EPIGENOMICS RELATED R&D, 2004-2015	59
TABLE 11 GLOBAL IMPACT OF CARDIOVASCULAR DISEASE, 2013 (MILLIONS)	65
TABLE 12 INDICATIONS AND OUTCOMES	81
TABLE 13 NORTH AMERICAN EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 (\$ MILLIONS)	85
TABLE 14 NORTH AMERICAN EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH 2020 (\$ MILLIONS)	86
TABLE 15 NORTH AMERICAN EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	86
TABLE 16 NORTH AMERICAN EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY, THROUGH 2020 (\$ MILLIONS)	86
TABLE 17 NORTH AMERICAN EPIGENOMIC MARKET BY APPLICATION AREA, THROUGH 2020 (\$ MILLIONS)	87
TABLE 18 NORTH AMERICAN EPIGENETIC PERSONALIZED MEDICINE FOR CANCER TREATMENT MARKET BY TYPE, THROUGH 2020 (\$ MILLIONS)	87
TABLE 19 NORTH AMERICAN EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 (\$ MILLIONS)	88
TABLE 20 NORTH AMERICAN EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BASED ON THERAPEUTICS, THROUGH 2020 (\$ MILLIONS)	89
TABLE 21 NORTH AMERICA EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, THROUGH 2020 (\$ MILLIONS)	89
TABLE 22 NORTH AMERICAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR OTHERS, THROUGH 2020 (\$ MILLIONS)	90
TABLE 23 NORTH AMERICAN EPIGENETIC THERAPIES MARKET, THROUGH 2020 (\$ MILLIONS)	90
TABLE 24 NORTH AMERICAN BIOMARKER MARKET, THROUGH 2020 (\$ MILLIONS)	91
TABLE 25 NORTH AMERICAN MARKET FOR HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION, THROUGH 2020 (\$ MILLIONS)	92
TABLE 26 NORTH AMERICAN EPIGENETIC DIAGNOSTIC MARKET, THROUGH 2020 (\$ MILLIONS)	92
TABLE 27 NORTH AMERICAN EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	93
TABLE 28 NORTH AMERICAN EPIGENETIC CARDIOVASCULAR DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	94

TABLE HEADING	PAGE NO.
TABLE 29 NORTH AMERICAN EPIGENETIC INFLAMMATORY AND AUTOIMMUNE DISEASE DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	94
TABLE 30 NORTH AMERICAN EPIGENOMIC RESEARCH AND DEVELOPMENT MARKET, THROUGH 2020 (\$ MILLIONS)	95
TABLE 31 ASIA-PACIFIC EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 (\$ MILLIONS)	97
TABLE 32 ASIA-PACIFIC EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH 2020 (\$ MILLIONS)	97
TABLE 33 ASIA-PACIFIC EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	98
TABLE 34 ASIA-PACIFIC EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY, THROUGH 2020 (\$ MILLIONS)	98
TABLE 35 ASIA-PACIFIC EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	99
TABLE 36 ASIA-PACIFIC EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR CANCER TREATMENT, THROUGH 2020 (\$ MILLIONS)	99
TABLE 37 ASIA-PACIFIC EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 (\$ MILLIONS)	100
TABLE 38 ASIA-PACIFIC EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BY THERAPEUTIC, THROUGH 2020 (\$ MILLIONS)	100
TABLE 39 ASIA-PACIFIC EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, THROUGH 2020 (\$ MILLIONS)	101
TABLE 40 ASIA-PACIFIC EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR OTHERS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	101
TABLE 41 ASIA-PACIFIC EPIGENETIC THERAPY MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	102
TABLE 42 ASIA-PACIFIC BIOMARKER MARKET, THROUGH 2020 (\$ MILLIONS)	103
TABLE 43 ASIA-PACIFIC HISTONIC MODIFICATION AS A BIOMARKER IN CANCER DETECTION MARKET, THROUGH 2020 (\$ MILLIONS)	104
TABLE 44 ASIA-PACIFIC EPIGENETIC DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	104
TABLE 45 ASIA-PACIFIC EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	105
TABLE 46 ASIA-PACIFIC EPIGENETIC MARKET FOR CARDIOVASCULAR DIAGNOSIS, THROUGH 2020 (\$ MILLIONS)	105
TABLE 47 ASIA-PACIFIC EPIGENETIC MARKET FOR INFLAMMATORY AND AUTOIMMUNE DISEASE DIAGNOSIS, THROUGH 2020 (\$ MILLIONS)	106
TABLE 48 ASIA-PACIFIC EPIGENETIC MARKET FOR RESEARCH AND DEVELOPMENT, THROUGH 2020 (\$ MILLIONS)	107
TABLE 49 EUROPEAN EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 (\$ MILLIONS)	109
TABLE 50 EUROPEAN EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH (\$ MILLIONS)	109
TABLE 51 EUROPEAN EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	110
TABLE 52 EUROPEAN EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY, THROUGH 2020 (\$ MILLIONS)	110
TABLE 53 EUROPEAN EPIGENOMIC MARKET BY APPLICATION AREA, THROUGH 2020 (\$ MILLIONS)	110
TABLE 54 EUROPEAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR CANCER TREATMENT BY DIAGNOSIS, THROUGH 2020 (\$ MILLIONS)	111

TABLE HEADING	PAGE NO.
TABLE 55 EUROPEAN EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 (\$ MILLIONS)	111
TABLE 56 EUROPEAN EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BASED ON THERAPEUTICS, THROUGH 2020 (\$ MILLIONS)	112
TABLE 57 EUROPEAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, THROUGH 2020 (\$ MILLIONS)	113
TABLE 58 EUROPEAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR OTHERS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	113
TABLE 59 EUROPEAN EPIGENETIC THERAPIES MARKET, THROUGH 2020 (\$ MILLIONS)	114
TABLE 60 EUROPEAN BIOMARKER MARKET, THROUGH 2020 (\$ MILLIONS)	115
TABLE 61 EUROPEAN HISTONIC MODIFICATION AS BIOMARKER MARKET IN CANCER DETECTION, THROUGH 2020 (\$ MILLIONS)	115
TABLE 62 EUROPEAN EPIGENETIC DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	116
TABLE 63 EUROPEAN EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	116
TABLE 64 EUROPEAN EPIGENETIC CARDIOVASCULAR DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	117
TABLE 65 EUROPEAN EPIGENETIC INFLAMMATORY AND AUTOIMMUNE DISEASE DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	117
TABLE 66 EUROPEAN EPIGENETIC RESEARCH AND DEVELOPMENT, THROUGH 2020 (\$ MILLIONS)	118
TABLE 67 LATIN AMERICAN EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 (\$ MILLIONS)	120
TABLE 68 LATIN AMERICAN EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH 2020 (\$ MILLIONS)	120
TABLE 69 LATIN AMERICAN EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	121
TABLE 70 LATIN AMERICAN EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY, THROUGH 2020 (\$ MILLIONS)	121
TABLE 71 LATIN AMERICAN EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	121
TABLE 72 LATIN AMERICAN EPIGENETIC PERSONALIZED MEDICINE FOR CANCER TREATMENT BY DIAGNOSIS, THROUGH 2020 (\$ MILLIONS)	122
TABLE 73 LATIN AMERICAN EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 (\$ MILLIONS)	123
TABLE 74 LATIN AMERICAN EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BASED ON THERAPEUTICS, THROUGH 2020 (\$ MILLIONS)	123
TABLE 75 LATIN AMERICAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, THROUGH 2020 (\$ MILLIONS)	124
TABLE 76 LATIN AMERICAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR OTHERS BY DIAGNOSIS, THROUGH 2020 (\$ MILLIONS)	124
TABLE 77 LATIN AMERICAN EPIGENETIC THERAPY MARKET, THROUGH 2020 (\$ MILLIONS)	125
TABLE 78 LATIN AMERICAN BIOMARKER MARKET, THROUGH 2020 (\$ MILLIONS)	126
TABLE 79 LATIN AMERICAN HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION MARKET, THROUGH 2020 (\$ MILLIONS)	126
TABLE 80 LATIN AMERICAN EPIGENETIC DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	127
TABLE 81 LATIN AMERICAN EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	127
TABLE 82 LATIN AMERICAN EPIGENETIC CARDIOVASCULAR DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	128

TABLE HEADING	PAGE NO.
TABLE 83 LATIN AMERICAN EPIGENETIC INFLAMMATORY AND AUTOIMMUNE DISEASE DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	129
TABLE 84 LATIN AMERICAN EPIGENETIC RESEARCH AND DEVELOPMENT, THROUGH 2020 (\$ MILLIONS)	129
TABLE 85 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 (\$ MILLIONS)	131
TABLE 86 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH 2020 (\$ MILLIONS)	131
TABLE 87 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	132
TABLE 88 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY, THROUGH 2020 (\$ MILLIONS)	132
TABLE 89 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY APPLICATION AREA, THROUGH 2020 (\$ MILLIONS)	133
TABLE 90 MIDDLE EAST AND AFRICA EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR CANCER TREATMENT BY TYPE, THROUGH 2020 (\$ MILLIONS)	133
TABLE 91 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 (\$ MILLIONS)	134
TABLE 92 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BASED ON THERAPEUTICS, THROUGH 2020 (\$ MILLIONS)	135
TABLE 93 MIDDLE EAST AND AFRICA EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, THROUGH 2020 (\$ MILLIONS)	135
TABLE 94 MIDDLE EAST AND AFRICA EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR OTHERS BY DIAGNOSIS, THROUGH 2020 (\$ MILLIONS)	135
TABLE 95 MIDDLE EAST AND AFRICA EPIGENETIC THERAPY MARKET, THROUGH 2020 (\$ MILLIONS)	136
TABLE 96 MIDDLE EAST AND AFRICA BIOMARKER MARKET, THROUGH 2020 (\$ MILLIONS)	137
TABLE 97 MIDDLE EAST AND AFRICA HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION MARKET, THROUGH 2020 (\$ MILLIONS)	138
TABLE 98 MIDDLE EAST AND AFRICA EPIGENETIC DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	138
TABLE 99 MIDDLE EAST AND AFRICA EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	138
TABLE 100 MIDDLE EAST AND AFRICA EPIGENETIC CARDIOVASCULAR DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	139
TABLE 101 MIDDLE EAST AND AFRICA EPIGENETIC INFLAMMATORY AND AUTOIMMUNE DISEASE DIAGNOSIS MARKET, THROUGH 2020 (\$ MILLIONS)	140
TABLE 102 MIDDLE EAST AND AFRICA EPIGENETIC RESEARCH AND DEVELOPMENT, THROUGH 2020 (\$ MILLIONS)	141
TABLE 103 GLOBAL EPIGENOMIC MARKET FOR REAGENTS BY REGION, THROUGH 2020 (\$ MILLIONS)	144
TABLE 104 GLOBAL EPIGENOMIC MARKET FOR KITS BY REGION, THROUGH 2020 (\$ MILLIONS)	146
TABLE 105 GLOBAL EPIGENOMIC MARKET FOR INSTRUMENTS BY REGION, THROUGH 2020 (\$ MILLIONS)	147
TABLE 106 GLOBAL EPIGENOMIC MARKET FOR ENZYMES BY REGION, THROUGH 2020 (\$ MILLIONS)	148
TABLE 107 GLOBAL EPIGENOMIC MARKET FOR SERVICES BY REGION, THROUGH 2020 (\$ MILLIONS)	150
TABLE 108 GLOBAL EPIGENOMIC MARKET IN DNA METHYLATION BY REGION, THROUGH 2020 (\$ MILLIONS)	153

TABLE HEADING	PAGE NO.
TABLE 109 GLOBAL EPIGENOMIC MARKET IN HISTONE METHYLATION AND ACETYLATION BY REGION, THROUGH 2020 (\$ MILLIONS)	154
TABLE 110 GLOBAL EPIGENOMIC MARKET IN MICRORNA MODIFICATION BY REGION, THROUGH 2020 (\$ MILLIONS)	155
TABLE 111 GLOBAL EPIGENOMIC MARKET IN ONCOLOGY BY REGION, THROUGH 2020 (\$ MILLIONS)	159
TABLE 112 GLOBAL EPIGENOMIC MARKET IN NON-ONCOLOGY, BY REGION, THROUGH 2020 (\$ MILLIONS)	160
TABLE 113 GLOBAL EPIGENOMIC MARKET IN DNA METHYLTRANSFERASE INHIBITORS BY REGION, THROUGH 2020 (\$ MILLIONS)	162
TABLE 114 GLOBAL EPIGENOMIC MARKET IN NON-ONCOLOGY BY REGION, THROUGH 2020 (\$ MILLIONS)	163
TABLE 115 GLOBAL EPIGENOMIC MARKET IN DIAGNOSIS BY REGION, THROUGH 2020 (\$ MILLIONS)	164
TABLE 116 GLOBAL EPIGENOMIC MARKET IN PROGNOSIS BY REGION, THROUGH 2020 (\$ MILLIONS)	166
TABLE 117 GLOBAL EPIGENOMIC MARKET FOR THERAPY OPTIMIZATION IN ROUTINE CLINICAL TREATMENT BY REGION, THROUGH 2020 (\$ MILLIONS)	167
TABLE 118 GLOBAL EPIGENOMIC MARKET IN DRUG DISCOVERY BY REGION, THROUGH 2020 (\$ MILLIONS)	169
TABLE 119 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR CANCER TREATMENT BY REGION, THROUGH 2020 (\$ MILLIONS)	172
TABLE 120 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS BY REGION, THROUGH 2020 (\$ MILLIONS)	173
TABLE 121 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR CARDIOVASCULAR DISEASE, BY REGION, THROUGH 2020 (\$ MILLIONS)	174
TABLE 122 GLOBAL EPIGENOMIC MARKET IN HEMATOLOGICAL CANCERS BY REGION, THROUGH 2020 (\$ MILLIONS)	176
TABLE 123 GLOBAL EPIGENOMIC MARKET IN SOLID TUMORS BY REGION, THROUGH 2020 (\$ MILLIONS)	178
TABLE 124 GLOBAL EPIGENOMIC MARKET IN GASTRIC CANCER BY REGION, THROUGH 2020 (\$ MILLIONS)	179
TABLE 125 GLOBAL EPIGENOMIC MARKET IN LUNG CANCER BY REGION, THROUGH 2020 (\$ MILLIONS)	181
TABLE 126 GLOBAL EPIGENOMIC MARKET IN HUNTINGTON'S DISEASE, BY REGION, THROUGH 2020 (\$ MILLIONS)	182
TABLE 127 GLOBAL EPIGENOMIC MARKET IN ALZHEIMER'S DISEASE BY REGION, THROUGH 2020 (\$ MILLIONS)	183
TABLE 128 GLOBAL EPIGENOMIC MARKET IN DEPRESSION BY REGION, THROUGH 2020 (\$ MILLIONS)	184
TABLE 129 GLOBAL EPIGENOMIC MARKET IN MENTAL RETARDATION BY REGION, THROUGH 2020 (\$ MILLIONS)	186
TABLE 130 GLOBAL EPIGENOMIC MARKET IN PARKINSON'S DISEASE, BY REGION, THROUGH 2020 (\$ MILLIONS)	187
TABLE 131 GLOBAL EPIGENOMIC MARKET IN MYELODYSPLASTIC SYNDROMES BY REGION, THROUGH 2020 (\$ MILLIONS)	188
TABLE 132 GLOBAL EPIGENOMIC MARKET IN OBESITY, BY REGION, THROUGH 2020 (\$ MILLIONS)	190
TABLE 133 GLOBAL EPIGENOMIC MARKET IN DIABETES BY REGION, THROUGH 2020 (\$ MILLIONS)	191
TABLE 134 GLOBAL EPIGENOMIC MARKET IN RHEUMATOID ARTHRITIS BY REGION, THROUGH 2020 (\$ MILLIONS)	192

TABLE HEADING	PAGE NO.
TABLE 135 GLOBAL EPIGENOMIC MARKET IN MULTIPLE SCLEROSIS BY REGION, THROUGH 2020 (\$ MILLIONS)	194
TABLE 136 GLOBAL EPIGENOMIC MARKET IN INFLAMMATORY BOWEL DISEASES BY REGION, THROUGH 2020 (\$ MILLIONS)	195
TABLE 137 GLOBAL EPIGENOMIC MARKET IN LUPUS BY REGION, THROUGH 2020 (\$ MILLIONS)	196
TABLE 138 GLOBAL EPIGENOMIC MARKET IN STEM CELL THERAPIES BY REGION, THROUGH 2020 (\$ MILLIONS)	197
TABLE 139 GLOBAL EPIGENOMIC MARKET IN TISSUE REENGINEERING BY REGION, THROUGH 2020 (\$ MILLIONS)	199
TABLE 140 GLOBAL EPIGENOMIC MARKET IN DIABETES BY REGION, THROUGH 2020 (\$ MILLIONS)	200
TABLE 141 GLOBAL EPIGENOMIC MARKET IN RHEUMATOID ARTHRITIS BY REGION, THROUGH 2020 (\$ MILLIONS)	201
TABLE 142 GLOBAL EPIGENOMIC MARKET IN MENTAL DISORDERS BY REGION, THROUGH 2020 (\$ MILLIONS)	203
TABLE 143 GLOBAL EPIGENOMIC MARKET IN CARDIAC DYSFUNCTION BY REGION, THROUGH 2020 (\$ MILLIONS)	204
TABLE 144 GLOBAL EPIGENOMIC MARKET IN CANCER BY REGION, THROUGH 2020 (\$ MILLIONS)	205
TABLE 145 GLOBAL EPIGENOMIC MARKET IN BIOMARKER DISCOVERY: DNA METHYLATION FOR CANCER DETECTION BY REGION, THROUGH 2020 (\$ MILLIONS)	207
TABLE 146 GLOBAL EPIGENOMIC MARKET IN HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION BY REGION, THROUGH 2020 (\$ MILLIONS)	208
TABLE 147 GLOBAL EPIGENOMIC MARKET IN CHROMATIN REMODELING BY REGION, THROUGH 2020 (\$ MILLIONS)	209
TABLE 148 GLOBAL EPIGENOMIC MARKET IN NONCODING RNAs BY REGION, THROUGH 2020 (\$ MILLIONS)	211
TABLE 149 GLOBAL EPIGENOMIC MARKET IN MIRNAS BY REGION, THROUGH 2020 (\$ MILLIONS)	212
TABLE 150 ABBOTT PRODUCT PORTFOLIO	214
TABLE 151 ABBOTT RECENT DEVELOPMENTS	214
TABLE 152 AFFYMETRIX PRODUCT PORTFOLIO	215
TABLE 153 AFFYMETRIX RECENT DEVELOPMENTS	215
TABLE 154 AGILENT PRODUCT PORTFOLIO	215
TABLE 155 AGILENT'S RECENT DEVELOPMENTS	216
TABLE 156 ASTELLAS PHARMACEUTICALS PRODUCT PORTFOLIO	216
TABLE 157 ASTELLAS PHARMACEUTICALS RECENT DEVELOPMENTS	217
TABLE 158 BAYER PRODUCT PORTFOLIO	217
TABLE 159 BAYER RECENT DEVELOPMENTS	218
TABLE 160 BIO VISION PRODUCT PORTFOLIO	218
TABLE 161 BIO VISION RECENT DEVELOPMENTS	218
TABLE 162 CELGENE PRODUCT PORTFOLIO	219
TABLE 163 EMD MILLIPORE PRODUCT PORTFOLIO	220
TABLE 164 EMD MILLIPORE RECENT DEVELOPMENTS	220
TABLE 165 EPIGENOMICS PRODUCT PORTFOLIO	220
TABLE 166 EPIGENOMICS RECENT DEVELOPMENTS	221
TABLE 167 EPIGENTEK PRODUCT PORTFOLIO	221
TABLE 168 EPIGENTEK RECENT DEVELOPMENTS	221
TABLE 169 GILEAD SCIENCES PRODUCT PORTFOLIO	222

TABLE HEADING	PAGE NO.
TABLE 170 GILEAD SCIENCES RECENT DEVELOPMENTS	223
TABLE 171 GLAXOSMITHKLINE PRODUCT PORTFOLIO	223
TABLE 172 ILLUMINA PRODUCT PORTFOLIO	224
TABLE 173 ILLUMINA RECENT DEVELOPMENTS	224
TABLE 174 JOHNSON & JOHNSON PRODUCT PORTFOLIO	225
TABLE 175 KARUS THERAPEUTICS PRODUCT PORTFOLIO	225
TABLE 176 LABCORP PRODUCT PORTFOLIO	226
TABLE 177 LABCORP RECENT DEVELOPMENTS	226
TABLE 178 LES LABORATOIRES SERVIER RECENT DEVELOPMENTS	226
TABLE 179 NOVARTIS PRODUCT PORTFOLIO	228
TABLE 180 NOVARTIS RECENT DEVELOPMENTS	228
TABLE 181 ONCOLYS BIOPHARMA PRODUCT PORTFOLIO	229
TABLE 182 ONCOLYS BIOPHARMA RECENT DEVELOPMENTS	229
TABLE 183 ORCHID CHEMICALS & PHARMACEUTICALS PRODUCT PORTFOLIO	230
TABLE 184 PROGEN PHARMA PRODUCT PORTFOLIO	230
TABLE 185 QUEST DIAGNOSTICS PRODUCT PORTFOLIO	231
TABLE 186 QUEST DIAGNOSTICS RECENT DEVELOPMENTS	231
TABLE 187 ROCHE'S PRODUCT PORTFOLIO	232
TABLE 188 ROCHE'S RECENT DEVELOPMENTS	232
TABLE 189 RUBICON GENOMICS PRODUCT PORTFOLIO	233
TABLE 190 RUBICON GENOMICS RECENT DEVELOPMENTS	233
TABLE 191 TAKEDA PHARMACEUTICALS PRODUCT PORTFOLIO	234
TABLE 192 U.S. PATENTS, 2011-JULY 2015	236
TABLE 193 EUROPEAN AND JAPANESE PATENTS, 2011-JULY 2015	242
TABLE 194 JAPANESE PATENTS, 2011--NOVEMBER 2014	242

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL EPIGENOMIC MARKET BY REGION, 2014-2020 (\$ MILLIONS)	7
FIGURE 1 AZAC AND 5-AZADC MECHANISM OF ACTION	24
FIGURE 2 EPIGENETIC CHANGES IN CANCER INVOLVING THE METHYLATION OF TUMOR-SUPPRESSION GENES AND THE DEMETHYLATION OF PROMETASTATIC GENES	26
FIGURE 3 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR CANCER TREATMENT, 2014-2020	36
FIGURE 4 POPULATION AGE 65 AND OLDER, 2010-2030 (%)	57
FIGURE 5 EPIGENOMIC ANALYSIS	62
FIGURE 6 POPULATION AFFECTED IN HIGH-, MIDDLE- AND LOW-INCOME COUNTRIES BY TYPE OF HEART DISEASE, 2012 (%)	66
FIGURE 7 GLOBAL CARDIOVASCULAR DISEASE PERCENTAGE, 2012 (%)	66
FIGURE 8 EPIGENETIC ADVANCEMENT IN CARDIOVASCULAR DISEASES	67
FIGURE 9 EPIGENETICS MECHANISM	70
FIGURE 10 NORTH AMERICAN EPIGENOMIC MARKET, 2014-2020 (\$ MILLIONS)	84
FIGURE 11 ASIA-PACIFIC EPIGENOMIC MARKET, 2014-2020 (\$ MILLIONS)	96
FIGURE 12 EUROPE EPIGENOMIC MARKET, 2014-2020 (\$ MILLIONS)	108
FIGURE 13 LATIN AMERICAN EPIGENOMIC MARKET, 2014-2020 (\$ MILLIONS)	119
FIGURE 14 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET, 2014-2020 (\$ MILLIONS)	130
FIGURE 15 GLOBAL EPIGENOMIC MARKET FOR REAGENTS, 2014-2020 (\$ MILLIONS)	143
FIGURE 16 GLOBAL EPIGENOMIC MARKET FOR KITS, 2014-2020 (\$ MILLIONS)	144
FIGURE 17 GLOBAL EPIGENOMIC MARKET FOR INSTRUMENTS, 2014-2020 (\$ MILLIONS)	146
FIGURE 18 GLOBAL EPIGENOMIC MARKET FOR ENZYMES, 2014-2020 (\$ MILLIONS)	147
FIGURE 19 GLOBAL EPIGENOMIC MARKET FOR SERVICES, 2014-2020 (\$ MILLIONS)	149
FIGURE 20 GLOBAL EPIGENOMIC MARKET IN DNA METHYLATION, 2014-2020 (\$ MILLIONS)	152
FIGURE 21 GLOBAL EPIGENOMIC MARKET IN HISTONE METHYLATION AND ACETYLATION, 2014-2020 (\$ MILLIONS)	153
FIGURE 22 GLOBAL EPIGENOMIC MARKET IN MICRORNA MODIFICATION, THROUGH 2020 (\$ MILLIONS)	155
FIGURE 23 GLOBAL EPIGENOMIC MARKET IN ONCOLOGY, 2014-2020 (\$ MILLIONS)	158
FIGURE 24 GLOBAL EPIGENOMIC MARKET IN NON-ONCOLOGY, 2014-2020 (\$ MILLIONS)	159
FIGURE 25 GLOBAL EPIGENOMIC MARKET IN DNA METHYLTRANSFERASE INHIBITORS, 2014-2020 (\$ MILLIONS)	161
FIGURE 26 GLOBAL EPIGENOMIC MARKET IN HISTONE DEACETYLASE INHIBITORS, 2014-2020 (\$ MILLIONS)	162
FIGURE 27 GLOBAL EPIGENOMIC MARKET IN DIAGNOSIS, 2014-2020 (\$ MILLIONS)	164
FIGURE 28 GLOBAL EPIGENOMIC MARKET IN PROGNOSIS, 2014-2020 (\$ MILLIONS)	165
FIGURE 29 GLOBAL EPIGENOMIC MARKET FOR THERAPY OPTIMIZATION IN ROUTINE CLINICAL TREATMENT, 2014-2020 (\$ MILLIONS)	166
FIGURE 30 GLOBAL EPIGENOMIC MARKET IN PROGNOSIS, 2014-2020 (\$ MILLIONS)	168
FIGURE 31 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR CANCER TREATMENT, 2014-2020 (\$ MILLIONS)	171
FIGURE 32 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS, 2014-2020 (\$ MILLIONS)	172
FIGURE 33 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR CARDIOVASCULAR DISEASE, 2014-2020 (\$ MILLIONS)	174

FIGURE TITLE	PAGE NO.
FIGURE 34 GLOBAL EPIGENOMIC MARKET IN HEMATOLOGICAL CANCERS, 2014-2020 (\$ MILLIONS)	175
FIGURE 35 GLOBAL EPIGENOMIC MARKET IN SOLID TUMORS, 2014-2020 (\$ MILLIONS)	177
FIGURE 36 GLOBAL EPIGENOMIC MARKET IN GASTRIC CANCER, 2014-2020 (\$ MILLIONS)	178
FIGURE 37 GLOBAL EPIGENOMIC MARKET IN LUNG CANCER, 2014-2020 (\$ MILLIONS)	180
FIGURE 38 GLOBAL EPIGENOMIC MARKET IN HUNTINGTON'S DISEASE, 2014-2020 (\$ MILLIONS)	181
FIGURE 39 GLOBAL EPIGENOMIC MARKET IN ALZHEIMER'S DISEASE, 2014-2020 (\$ MILLIONS)	182
FIGURE 40 GLOBAL EPIGENOMIC MARKET IN DEPRESSION, 2014-2020 (\$ MILLIONS)	184
FIGURE 41 GLOBAL EPIGENOMIC MARKET IN MENTAL RETARDATION, 2014-2020 (\$ MILLIONS)	185
FIGURE 42 GLOBAL EPIGENOMIC MARKET IN PARKINSON'S DISEASE, 2014-2020 (\$ MILLIONS)	186
FIGURE 43 GLOBAL EPIGENOMIC MARKET IN MYELODYSPLASTIC SYNDROMES, 2014-2020 (\$ MILLIONS)	188
FIGURE 44 GLOBAL EPIGENOMIC MARKET IN OBESITY, 2014-2020 (\$ MILLIONS)	189
FIGURE 45 GLOBAL EPIGENOMIC MARKET IN DIABETES, 2014-2020 (\$ MILLIONS)	190
FIGURE 46 GLOBAL EPIGENOMIC MARKET IN RHEUMATOID ARTHRITIS, 2014-2020 (\$ MILLIONS)	191
FIGURE 47 GLOBAL EPIGENOMIC MARKET IN MULTIPLE SCLEROSIS, 2014-2020 (\$ MILLIONS)	193
FIGURE 48 GLOBAL EPIGENOMIC MARKET IN INFLAMMATORY BOWEL DISEASES, 2014-2020 (\$ MILLIONS)	194
FIGURE 49 GLOBAL EPIGENOMIC MARKET IN LUPUS, 2014-2020 (\$ MILLIONS)	195
FIGURE 50 GLOBAL EPIGENOMIC MARKET IN STEM CELL THERAPIES, 2014-2020 (\$ MILLIONS)	197
FIGURE 51 GLOBAL EPIGENOMIC MARKET IN TISSUE RE-ENGINEERING, 2014-2020 (\$ MILLIONS)	198
FIGURE 52 GLOBAL EPIGENOMIC MARKET IN DIABETES, 2014-2020 (\$ MILLIONS)	199
FIGURE 53 GLOBAL EPIGENOMIC MARKET IN RHEUMATOID ARTHRITIS, 2014-2020 (\$ MILLIONS)	201
FIGURE 54 GLOBAL EPIGENOMIC MARKET IN MENTAL DISORDERS, 2014-2020 (\$ MILLIONS)	202
FIGURE 55 GLOBAL EPIGENOMIC MARKET IN CARDIAC DYSFUNCTION, 2014-2020 (\$ MILLIONS)	203
FIGURE 56 GLOBAL EPIGENOMIC MARKET IN CANCER, 2014-2020 (\$ MILLIONS)	205
FIGURE 57 GLOBAL EPIGENOMIC MARKET IN DNA METHYLATION FOR CANCER DETECTION, 2014-2020 (\$ MILLIONS)	206
FIGURE 58 GLOBAL EPIGENOMIC MARKET IN HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION, 2014-2020 (\$ MILLIONS)	207
FIGURE 59 GLOBAL EPIGENOMICS MARKET IN CHROMATIN REMODELING, 2014-2020 (\$ MILLIONS)	208
FIGURE 60 GLOBAL EPIGENOMIC MARKET IN NONCODING RNAS, 2014-2020 (\$ MILLIONS)	210
FIGURE 61 GLOBAL EPIGENOMIC MARKET IN MIRNAS, 2014-2020 (\$ MILLION)	211